tarcocimab tedromer + tabirafusp tedromer

A **combination of two investigational biologic drugs**, tarcocimab tedromer and tabirafusp tedromer, both administered by intravitreal injection for the treatment of neovascular (wet) age-related macular degeneration (AMD)[1][3][4][13][17][20]. Tarcocimab tedromer is an **antibody biopolymer conjugate (ABC)** targeting **vascular endothelial growth factor (VEGF)**, designed for high durability and potent VEGF inhibition in retinal tissues[1][7][10][17]. Tabirafusp tedromer is another ABC biologic, engineered to inhibit **both VEGF and interleukin-6 (IL-6)**, aiming to modulate disease pathways with dual-targeting for improved outcomes[1][18]. Both are developed on Kodiak Sciences’ ABC platform, optimized for prolonged ocular tissue activity and reduced treatment burden. The combination’s mechanism is intended to synergistically suppress angiogenesis and key inflammatory signaling in wet AMD, which is characterized by abnormal blood vessel growth in the retina leading to vision loss[1][3][17]. The combination is currently in Phase 3 clinical trials (DAYBREAK trial) as a potentially novel approach to more effective wet AMD management[3][4][13][15][17][20].

Brand names

No known commercial brand or trade names for the combination at this time

Other names

tarcocimab tedromer and tabirafusp tedromerKSI-301 + KSI-501